Mars

Last updated January 31, 2026

Innovation Areas

2,578

Inventors

Collaborations

Rna expression signature profiling: MarsRecent Research Landscape

Ineffective targeting of pancreatic cancer leads to high treatment failure and wasted clinical costs, which is mitigated by engineering SIGMAR1 ligands mapped to specific RNA expression profiles. This allows for precise molecular control over drug sensitivity in PDAC patients.

What technical problems is Mars addressing in Rna expression signature profiling?

Uncontrolled malignant cell proliferation

(11)evidences

Tumors frequently develop mechanisms to evade standard immunotherapy or lack recognizable surface antigens. Targeting self-peptides and overcoming checkpoint insensitivity expands the range of treatable non-responsive malignancies.

Unpredictable therapeutic response variability

(5)evidences

Clinical outcomes for cancer and liver diseases vary significantly between patients despite similar diagnoses. Identifying these underlying differences allows for the mitigation of ineffective treatment selection and late-stage diagnostic failure.